Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the closing of its initial public offering of an aggregate 28,750,000...